Ann: Veyonda and Radiotherapy Delivers Clinical Benefits, page-3

Still early days, the journey continues though it appears. Very encouraging for all holders.

“The 24-week data is going to be even more important because we are seeing PSA levels in some men still falling at the 12-week point. The 24-week data will provide a much clearer picture of the full extent of the clinical benefit and be a strong pointer to just how beneficial the treatment is likely to have on survival times. But even before that point, the Company believes that this 12-week data justifies its belief that Veyonda is a potentially transformative anti-cancer drug. ”The end-of-study 24-week results for these cohorts are expected to be announced in early May. The 12-week and 24-week data for the 12 patients in the second phase of the trial are expected to be available in July and October, respectively.

These dates will coincide (ballpark) with release of LuPIN-1 data. 

Keep up the good work gang.